Santiago Manuel Cayetano Lopez
Research Subjects
Santiago Manuel Cayetano Lopez has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Alon Yehoshua
Pfizer Inc., New York, NY 10001, USA
3 shared publications - Kathleen Michelle Andersen
Pfizer Inc., New York, New York, United States
3 shared publications - Manuela Di Fusco
Pfizer Inc., New York, NY 10001, USA
3 shared publications Anan Zhou
Real-World Evidence, Genesis Research Group , Hoboken, NJ 07030
2 shared publications- Farid Khan
Pfizer, New York, USA
2 shared publications - Jazmine S. Mateus
Genesis Research Group, Hoboken, New Jersey, United States
2 shared publications
Latest Publications
- Open Access
- 1 September 2026
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 29 (1) , 2241-2250
Costs and healthcare resource utilization after COVID-19 hospitalization among US Medicare patients: a retrospective claims analysis
The COVID-19 pandemic has imposed substantial clinical and economic burdens on healthcare systems, with older adults disproportionately affected by severe outcomes1,2. Advanced age, multimorbidity,...
- 1 September 2026
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 29 (1) , 2241-2250
Open AccessCosts and healthcare resource utilization after COVID-19 hospitalization among US Medicare patients: a retrospective claims analysis
The COVID-19 pandemic has imposed substantial clinical and economic burdens on healthcare systems, with older adults disproportionately affected by severe outcomes1,2. Advanced age, multimorbidity,...
- Open Access
- 24 July 2026
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 15 (10) , 2627-2643
The Impact of Influenza on Health-Related Quality of Life, Work Productivity, and Activity Impairment Among Symptomatic US Patients with Influenza
- 24 July 2026
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 15 (10) , 2627-2643
Open AccessThe Impact of Influenza on Health-Related Quality of Life, Work Productivity, and Activity Impairment Among Symptomatic US Patients with Influenza
- Open Access
- 13 November 2025
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 195 (2) , 596-601
Enhancing COVID-19 vaccine effectiveness evidence generation using tokenized immunization registries
Purpose: To describe a novel data ecosystem and quantify improvements in documented COVID-19 vaccine uptake using closed claims data and state vaccine registries. Methods: De-identified data from administrative claims were linked via tokenization to state vaccine registry data from two states with mandatory vaccine reporting. COVID-19 vaccine uptake in claims alone versus supplemented with registry data was measured separately for original wildtype, BA.4/5-adapted bivalent, and XBB.1.5-adapted formulations. Results: There were over 9 million individuals included in each formulation distribution study period. Using claims data alone versus with additional state registry data, 20% versus 57% of individuals had documented receipt of a primary wildtype series (≥2 doses of two-dose or ≥ 1 of single-dose series), 7% versus 10% BA.4/5-adapted bivalent, and 6% versus 8% XBB.1.5-adapted COVID-19 vaccine. Most claims-based vaccination events were captured with drug, rather than procedure, codes. Individuals with Medicaid-based insurance were less likely to be captured as vaccinated in claims data. Conclusions: The addition of state vaccine registries increased COVID-19 vaccine capture by 182% for primary wildtype series, 41% BA.4/5-adapted bivalent, and 38% XBB.1.5-adapted formulations. Tokenization of claims data to vaccine registries presents an opportunity for more accurate estimates of vaccine uptake and effectiveness than claims data alone.
- 13 November 2025
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 195 (2) , 596-601
Open AccessEnhancing COVID-19 vaccine effectiveness evidence generation using tokenized immunization registries
Purpose: To describe a novel data ecosystem and quantify improvements in documented COVID-19 vaccine uptake using closed claims data and state vaccine registries. Methods: De-identified data from administrative claims were linked via tokenization to state vaccine registry data from two states with mandatory vaccine reporting. COVID-19 vaccine uptake in claims alone versus supplemented with registry data was measured separately for original wildtype, BA.4/5-adapted bivalent, and XBB.1.5-adapted formulations. Results: There were over 9 million individuals included in each formulation distribution study period. Using claims data alone versus with additional state registry data, 20% versus 57% of individuals had documented receipt of a primary wildtype series (≥2 doses of two-dose or ≥ 1 of single-dose series), 7% versus 10% BA.4/5-adapted bivalent, and 6% versus 8% XBB.1.5-adapted COVID-19 vaccine. Most claims-based vaccination events were captured with drug, rather than procedure, codes. Individuals with Medicaid-based insurance were less likely to be captured as vaccinated in claims data. Conclusions: The addition of state vaccine registries increased COVID-19 vaccine capture by 182% for primary wildtype series, 41% BA.4/5-adapted bivalent, and 38% XBB.1.5-adapted formulations. Tokenization of claims data to vaccine registries presents an opportunity for more accurate estimates of vaccine uptake and effectiveness than claims data alone.
- Open Access
2024-2025 BNT162b2 COVID-19 vaccine effectiveness in non-immunocompromised adults: mid-season estimates from vaccine registries in two states linked to administrative claims
Background: Data are limited on 2024-2025 BNT162b2 COVID-19 vaccine effectiveness (VE). Methods: Retrospective cohort study among non-immunocompromised adults from August 22, 2024 (“index”) to December 31, 2024, among residents of California or Louisiana continuously enrolled in health insurance plans reporting to HealthVerity for ≥1 year prior to index. Receipt of 2024-2025 BNT162b2 COVID-19 vaccine was defined using state vaccine registries with health insurance claims, using a time-varying exposure definition. VE against COVID-19-associated hospital admissions was estimated as (1-hazard ratio), using adjusted Cox proportional hazards models with 95% confidence intervals (CI). Results: Overall, 6,900,361 individuals met selection criteria for the study. By the end of follow-up (median 4.4 months), 325,362 (4.7%) had received a BNT162b2 2024-2025 COVID-19 vaccine dose. VE against COVID-19-associated hospital admission was 41% (95% CI 2-64). Discussion: The 2024-2025 formulation of BNT162b2 COVID-19 vaccine provided significant protection, particularly for older adults, in mid-season estimates. This study is registered on clinicaltrials.gov as NCT06923137 .
Open Access2024-2025 BNT162b2 COVID-19 vaccine effectiveness in non-immunocompromised adults: mid-season estimates from vaccine registries in two states linked to administrative claims
Background: Data are limited on 2024-2025 BNT162b2 COVID-19 vaccine effectiveness (VE). Methods: Retrospective cohort study among non-immunocompromised adults from August 22, 2024 (“index”) to December 31, 2024, among residents of California or Louisiana continuously enrolled in health insurance plans reporting to HealthVerity for ≥1 year prior to index. Receipt of 2024-2025 BNT162b2 COVID-19 vaccine was defined using state vaccine registries with health insurance claims, using a time-varying exposure definition. VE against COVID-19-associated hospital admissions was estimated as (1-hazard ratio), using adjusted Cox proportional hazards models with 95% confidence intervals (CI). Results: Overall, 6,900,361 individuals met selection criteria for the study. By the end of follow-up (median 4.4 months), 325,362 (4.7%) had received a BNT162b2 2024-2025 COVID-19 vaccine dose. VE against COVID-19-associated hospital admission was 41% (95% CI 2-64). Discussion: The 2024-2025 formulation of BNT162b2 COVID-19 vaccine provided significant protection, particularly for older adults, in mid-season estimates. This study is registered on clinicaltrials.gov as NCT06923137 .
- Open Access
- 26 October 2024
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 27 (1) , 1372-1378
Health outcomes and economic burden among patients with a COVID-19-associated hospitalization in the United States during the predominance of the XBB and JN.1 omicron lineages
Conduct a comprehensive analysis of the health and economic outcomes of patients with a COVID-19-associated hospitalization in the US during the predominance of the XBB and JN.1 Omicron lineages. This analysis used data from the PINC AI Healthcare Database (PHD) for all patients with a hospital admission date occurring between February 4, 2023, and February 29, 2024 with an ICD-10-CM code U07.1 "COVID-19" in any position. The data were used to estimate the mean and median length of stay (LOS), mean and median hospitalization cost, and proportion of patients that died in the hospital, by age and level of care (normal ward, intensive care [ICU], invasive mechanical ventilation [IMV]). LOS, hospitalization costs, and inpatient mortality increased with both the level of care and age. Patients not receiving ICU care had the shortest LOS, lowest inpatient mortality, and lowest hospitalization costs. LOS, hospitalization costs, and inpatient mortality were higher for those receiving ICU care and highest for those receiving IMV in the ICU. Within each level of care (normal ward, ICU without IMV, and ICU with IMV), the LOS, inpatient mortality, and hospitalization cost generally increased with age, indicating that older adults with COVID-19 required a longer recovery period, have a higher likelihood of death, and accrue higher costs. However, the proportion of pediatric patients with an ICU admission and/or IMV usage remained high. The PHD data may not be representative of all hospitalized patients in the US. These findings suggest that COVID-19 continues to have severe and costly consequences in all age groups, but particularly for older adults including long LOS, ICU admission, need for IMV, mortality, and high hospital costs.
- 26 October 2024
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 27 (1) , 1372-1378
Open AccessHealth outcomes and economic burden among patients with a COVID-19-associated hospitalization in the United States during the predominance of the XBB and JN.1 omicron lineages
Conduct a comprehensive analysis of the health and economic outcomes of patients with a COVID-19-associated hospitalization in the US during the predominance of the XBB and JN.1 Omicron lineages. This analysis used data from the PINC AI Healthcare Database (PHD) for all patients with a hospital admission date occurring between February 4, 2023, and February 29, 2024 with an ICD-10-CM code U07.1 "COVID-19" in any position. The data were used to estimate the mean and median length of stay (LOS), mean and median hospitalization cost, and proportion of patients that died in the hospital, by age and level of care (normal ward, intensive care [ICU], invasive mechanical ventilation [IMV]). LOS, hospitalization costs, and inpatient mortality increased with both the level of care and age. Patients not receiving ICU care had the shortest LOS, lowest inpatient mortality, and lowest hospitalization costs. LOS, hospitalization costs, and inpatient mortality were higher for those receiving ICU care and highest for those receiving IMV in the ICU. Within each level of care (normal ward, ICU without IMV, and ICU with IMV), the LOS, inpatient mortality, and hospitalization cost generally increased with age, indicating that older adults with COVID-19 required a longer recovery period, have a higher likelihood of death, and accrue higher costs. However, the proportion of pediatric patients with an ICU admission and/or IMV usage remained high. The PHD data may not be representative of all hospitalized patients in the US. These findings suggest that COVID-19 continues to have severe and costly consequences in all age groups, but particularly for older adults including long LOS, ICU admission, need for IMV, mortality, and high hospital costs.
- Open Access
- 28 September 2023
- Published by Springer Nature in Pediatric Research
- Vol. 95 (3) , 835-842
Enabling methanol fixation of pediatric nasal wash during respiratory illness for single cell sequencing in comparison with fresh samples
Background Lower respiratory tract infection (LRTI) including pneumonia, bronchitis, and bronchiolitis is the sixth leading cause of mortality around the world and leading cause of death in children under 5 years. Systemic immune response to viral infection is well characterized. However, there is little data regarding the immune response at the upper respiratory tract mucosa. The upper respiratory mucosa is the site of viral entry, initial replication and the first barrier against respiratory infections. Lower respiratory tract samples can be challenging to obtain and require more invasive procedures. However, nasal wash (NW) samples from the upper respiratory tract can be obtained with minimal discomfort to the patient. Method In a pilot study, we developed a protocol using NW samples obtained from hospitalized children with LRTI that enables single cell RNA sequencing (scRNA-seq) after the NW sample is methanol-fixed. Results We found no significant changes in scRNA-seq qualitative and quantitative parameters between methanol-fixed and fresh NW samples. Conclusions We present a novel protocol to enable scRNA-seq in NW samples from children admitted with LRTI. With the inherent challenges associated with clinical samples, the protocol described allows for processing flexibility as well as multicenter collaboration. Impact There are no significant differences in scRNA-seq qualitative and quantitative parameters between methanol fixed and fresh Pediatric Nasal wash samples. The study demonstrates the effectiveness of methanol fixation process on preserving respiratory samples for single cell sequencing. This enables Pediatric Nasal wash specimen for single cell RNA sequencing in pediatric patients with respiratory tract infection and allows processing flexibility and multicenter collaboration.
- 28 September 2023
- Published by Springer Nature in Pediatric Research
- Vol. 95 (3) , 835-842
Open AccessEnabling methanol fixation of pediatric nasal wash during respiratory illness for single cell sequencing in comparison with fresh samples
Background Lower respiratory tract infection (LRTI) including pneumonia, bronchitis, and bronchiolitis is the sixth leading cause of mortality around the world and leading cause of death in children under 5 years. Systemic immune response to viral infection is well characterized. However, there is little data regarding the immune response at the upper respiratory tract mucosa. The upper respiratory mucosa is the site of viral entry, initial replication and the first barrier against respiratory infections. Lower respiratory tract samples can be challenging to obtain and require more invasive procedures. However, nasal wash (NW) samples from the upper respiratory tract can be obtained with minimal discomfort to the patient. Method In a pilot study, we developed a protocol using NW samples obtained from hospitalized children with LRTI that enables single cell RNA sequencing (scRNA-seq) after the NW sample is methanol-fixed. Results We found no significant changes in scRNA-seq qualitative and quantitative parameters between methanol-fixed and fresh NW samples. Conclusions We present a novel protocol to enable scRNA-seq in NW samples from children admitted with LRTI. With the inherent challenges associated with clinical samples, the protocol described allows for processing flexibility as well as multicenter collaboration. Impact There are no significant differences in scRNA-seq qualitative and quantitative parameters between methanol fixed and fresh Pediatric Nasal wash samples. The study demonstrates the effectiveness of methanol fixation process on preserving respiratory samples for single cell sequencing. This enables Pediatric Nasal wash specimen for single cell RNA sequencing in pediatric patients with respiratory tract infection and allows processing flexibility and multicenter collaboration.
- Open Access
- 11 September 2023
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 11, 1261046
Clinical outcomes of COVID-19 and influenza in hospitalized children <5 years in the US
Introduction: We compared hospitalization outcomes of young children hospitalized with COVID-19 to those hospitalized with influenza in the United States.Methods: Patients aged 0-n = 4,839; median age: 0 years), 21.3% had an ICU admission, 19.6% received oxygen supplementation, 7.9% received MV support, and 0.5% died. Among children hospitalized with influenza (n = 4,349; median age: 1 year), 17.4% were admitted to the ICU, 26.7% received oxygen supplementation, 7.6% received MV support, and 0.3% died. Compared to children hospitalized with influenza, those with COVID-19 were more likely to have an ICU admission (adjusted odds ratio [aOR]: 1.34; 95% confidence interval [CI]: 1.21–1.48). However, children with COVID-19 were less likely to receive oxygen supplementation (aOR: 0.71; 95% CI: 0.64–0.78), have a prolonged LOS (aOR: 0.81; 95% CI: 0.75–0.88), or a prolonged ICU stay (aOR: 0.56; 95% CI: 0.46–0.68). The likelihood of receiving MV was similar (aOR: 0.94; 95% CI: 0.81, 1.1).Conclusions: Hospitalized children with either SARS-CoV-2 or influenza had severe complications including ICU admission and oxygen supplementation. Nearly 10% received MV support. Both SARS-CoV-2 and influenza have the potential to cause severe illness in young children.
- 11 September 2023
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 11, 1261046
Open AccessClinical outcomes of COVID-19 and influenza in hospitalized children <5 years in the US
Introduction: We compared hospitalization outcomes of young children hospitalized with COVID-19 to those hospitalized with influenza in the United States.Methods: Patients aged 0-n = 4,839; median age: 0 years), 21.3% had an ICU admission, 19.6% received oxygen supplementation, 7.9% received MV support, and 0.5% died. Among children hospitalized with influenza (n = 4,349; median age: 1 year), 17.4% were admitted to the ICU, 26.7% received oxygen supplementation, 7.6% received MV support, and 0.3% died. Compared to children hospitalized with influenza, those with COVID-19 were more likely to have an ICU admission (adjusted odds ratio [aOR]: 1.34; 95% confidence interval [CI]: 1.21–1.48). However, children with COVID-19 were less likely to receive oxygen supplementation (aOR: 0.71; 95% CI: 0.64–0.78), have a prolonged LOS (aOR: 0.81; 95% CI: 0.75–0.88), or a prolonged ICU stay (aOR: 0.56; 95% CI: 0.46–0.68). The likelihood of receiving MV was similar (aOR: 0.94; 95% CI: 0.81, 1.1).Conclusions: Hospitalized children with either SARS-CoV-2 or influenza had severe complications including ICU admission and oxygen supplementation. Nearly 10% received MV support. Both SARS-CoV-2 and influenza have the potential to cause severe illness in young children.
- 5 December 2022
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 42 (3) , e84-e87
“Hot Tub Lung” With M. avium complex in an Immunocompetent Adolescent
We describe a case of pulmonary Mycobacterium avium complex (MAC) infection in an immunocompetent pediatric patient after a hot tub near drowning event with a literature review of pediatric MAC-associated disease after hot tub exposure.
- 5 December 2022
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 42 (3) , e84-e87
“Hot Tub Lung” With M. avium complex in an Immunocompetent Adolescent
We describe a case of pulmonary Mycobacterium avium complex (MAC) infection in an immunocompetent pediatric patient after a hot tub near drowning event with a literature review of pediatric MAC-associated disease after hot tub exposure.
- 23 November 2021
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 41 (3) , 205-210
Disparities in Outcomes During Lower Respiratory Tract Infection in American Indian Children
Background: American Indian (AI) children are at increased risk for severe disease during lower respiratory tract infection (LRTI). The reasons for this increased severity are poorly understood. The objective of this study was to define the clinical presentations of LRTI and highlight the differences between AI and non-AI previously healthy patients under the age of 24 months. Methods: We performed a retrospective chart review between October 2010 and December 2019. We reviewed 1245 patient charts and 691 children met inclusion criteria for this study. Data records included demographics, clinical, laboratory data, and illness outcomes. Results: Of 691 patients, 120 were AI and 571 were non-AI. There was a significant difference in breast-feeding history (10% of AI vs. 28% of non-AI, P < 0.0001) and in secondhand smoke exposure (37% of AI vs. 21% of non-AI, P < 0.0001). AI children had increased length of hospitalization compared with non-AI children (median of 3 vs. 2 days, P < 0.001). In addition, AI children had higher rates of pediatric intensive unit admission (30%, n = 37) compared with non-AI children (11%; n = 67, P < 0.01). AI children also had higher rates (62.5%, n = 75) and duration of oxygen supplementation (median 3 days) than non-AI children (48%, n = 274, P = 0.004; median 2 days, P = 0.0002). On a multivariate analysis, AI race was an independent predictor of severe disease during LRTI. Conclusions: AI children have increased disease severity during LRTI with longer duration of hospitalization and oxygen supplementation, a higher rate of oxygen requirement and Powered by Editorial Manager and ProduXion Manager from Aries Systems Corporation pediatric intensive care unit admissions, and a greater need for mechanical ventilation. These results emphasize the need for improvement in health policies and access to health care in this vulnerable population.
- 23 November 2021
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 41 (3) , 205-210
Disparities in Outcomes During Lower Respiratory Tract Infection in American Indian Children
Background: American Indian (AI) children are at increased risk for severe disease during lower respiratory tract infection (LRTI). The reasons for this increased severity are poorly understood. The objective of this study was to define the clinical presentations of LRTI and highlight the differences between AI and non-AI previously healthy patients under the age of 24 months. Methods: We performed a retrospective chart review between October 2010 and December 2019. We reviewed 1245 patient charts and 691 children met inclusion criteria for this study. Data records included demographics, clinical, laboratory data, and illness outcomes. Results: Of 691 patients, 120 were AI and 571 were non-AI. There was a significant difference in breast-feeding history (10% of AI vs. 28% of non-AI, P < 0.0001) and in secondhand smoke exposure (37% of AI vs. 21% of non-AI, P < 0.0001). AI children had increased length of hospitalization compared with non-AI children (median of 3 vs. 2 days, P < 0.001). In addition, AI children had higher rates of pediatric intensive unit admission (30%, n = 37) compared with non-AI children (11%; n = 67, P < 0.01). AI children also had higher rates (62.5%, n = 75) and duration of oxygen supplementation (median 3 days) than non-AI children (48%, n = 274, P = 0.004; median 2 days, P = 0.0002). On a multivariate analysis, AI race was an independent predictor of severe disease during LRTI. Conclusions: AI children have increased disease severity during LRTI with longer duration of hospitalization and oxygen supplementation, a higher rate of oxygen requirement and Powered by Editorial Manager and ProduXion Manager from Aries Systems Corporation pediatric intensive care unit admissions, and a greater need for mechanical ventilation. These results emphasize the need for improvement in health policies and access to health care in this vulnerable population.
- 25 August 2020
- Published by Wiley in Pediatric Transplantation
- Vol. 25 (5) , e13823
Bartonella henselae infection in the pediatric solid organ transplant recipient
Bartonella henselae infection can cause a wide spectrum of diseases in both the immunocompetent and immunocompromised host with BA a severe form relegated to immunocompromised hosts, including solid organ transplant population. There are established criteria for diagnosis of Bartonella infection based on clinical presentation, serologic testing, imaging studies and, when indicated, tissue sampling for histopathological evaluation, particularly for BA. However, treatment recommendations for BA are inconclusive. Furthermore, there are no studies in the pediatric solid organ transplant population for antimicrobial therapy during BA secondary to Bartonella henselae infection. A case of BA following heart transplant is presented along with a literature review of clinical presentation; diagnosis and therapy for BA in the pediatric solid organ transplant population.
- 25 August 2020
- Published by Wiley in Pediatric Transplantation
- Vol. 25 (5) , e13823
Bartonella henselae infection in the pediatric solid organ transplant recipient
Bartonella henselae infection can cause a wide spectrum of diseases in both the immunocompetent and immunocompromised host with BA a severe form relegated to immunocompromised hosts, including solid organ transplant population. There are established criteria for diagnosis of Bartonella infection based on clinical presentation, serologic testing, imaging studies and, when indicated, tissue sampling for histopathological evaluation, particularly for BA. However, treatment recommendations for BA are inconclusive. Furthermore, there are no studies in the pediatric solid organ transplant population for antimicrobial therapy during BA secondary to Bartonella henselae infection. A case of BA following heart transplant is presented along with a literature review of clinical presentation; diagnosis and therapy for BA in the pediatric solid organ transplant population.